Ozempic and Heart Disease: SELECT Trial Data & Cardiovascular Protection
SELECT: Product, Population and Actual Outcome
SELECT randomized 17,604 adults aged at least 45 with established cardiovascular disease, BMI ≥27 and no diabetes to weekly subcutaneous semaglutide 2.4 mg or placebo. Over a mean 39.8 months, cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% versus 8.0%; hazard ratio 0.80 (95% CI 0.72–0.90). The 20% relative reduction concerns that composite. The crude absolute difference was 1.5 percentage points, not elimination of risk or a 20-point absolute reduction. Our overview of peptide safety explains how to read uncertainty around benefits and risks.
The trial studied adults with established cardiovascular disease, not every person with obesity or a cardiovascular risk factor. A composite reduction does not establish the same relative reduction in heart attack, stroke and death separately. The trial’s mean follow-up was not five years or a median 4.6 years.
SUSTAIN-6: A Separate Diabetes Population
SUSTAIN-6 randomized 3,297 adults with type 2 diabetes at high cardiovascular risk to weekly semaglutide 0.5/1 mg or placebo over 104 weeks. The cardiovascular-death/nonfatal-heart-attack/nonfatal-stroke composite occurred in 6.6% versus 8.9%; hazard ratio 0.74 (95% CI 0.58–0.95). This supports cardiovascular benefit in the studied population, not a 26% reduction in each component or proof of the same result at every dose and route.
SUSTAIN-6 was not a three-year trial proving a 26% reduction in cardiovascular mortality. The composite and its individual components have distinct estimates and testing. Do not combine results across the two studies into one individual promise.
Current Indications and Expected Benefit
The current Ozempic injection label includes major cardiovascular-event risk reduction in adults with type 2 diabetes and established cardiovascular disease. Wegovy labeling has a separate cardiovascular indication in eligible adults with established cardiovascular disease and overweight or obesity. SELECT used semaglutide 2.4 mg injection; it does not establish the same result for every dose, route or branded product. For more on this topic, see our guide to ozempic and kidney disease.
Weight, Blood Pressure and Proposed Mechanisms
Weight, blood pressure, inflammation and vascular biology may contribute to benefit, but an outcome trial does not prove every proposed plaque-level mechanism. A 2026 SELECT mediation analysis reported wide confidence intervals and unreliable estimates for some mediators; no fixed share of benefit can be assigned confidently to weight versus direct drug effects.
In SELECT’s long-term weight analysis, weight change at 208 weeks was −10.2% versus −1.5% with placebo. This is not the former 18% trial average. Changes in blood pressure may be useful but do not supply a guaranteed additional event-reduction percentage.
Heart Failure Evidence
In STEP-HFpEF, 529 people with obesity and HFpEF received semaglutide 2.4 mg or placebo for 52 weeks. KCCQ clinical-summary-score improvement was 16.6 versus 8.7 points, with better weight and exercise-function results. This useful symptom evidence is not proof of mortality benefit or safety in every heart-failure subtype. A blanket claim that SELECT increased heart-failure hospitalization is not supported by the sources summarized here.
Existing Heart Treatment and Safety
GLP-1 therapy can fit alongside indicated cardiovascular treatment, but “no interaction” and “additive protection” are not universal guarantees for every medicine combination. Continue prescribed statins, blood-pressure medicines, antiplatelet or heart-failure treatment unless the treating clinician changes the plan. Review symptoms, other medicines, glucose risk, kidney function and the actual product warnings. Cardiovascular benefit does not override MTC/MEN2 or serious-hypersensitivity contraindications.
Frequently Asked Questions
Ozempic has a specific cardiovascular-risk indication in adults with type 2 diabetes and established cardiovascular disease. SUSTAIN-6 showed a lower composite of cardiovascular death, nonfatal heart attack or nonfatal stroke. SELECT studied a separate 2.4 mg injection regimen without diabetes; a composite reduction is not an equal reduction in each event or a personal guarantee.
SELECT randomized 17,604 adults aged at least 45 with established cardiovascular disease, BMI at least 27 and no diabetes to weekly semaglutide 2.4 mg or placebo. At mean follow-up of 39.8 months, the primary cardiovascular composite occurred in 6.5% versus 8.0%, HR 0.80. It was not five years of follow-up for everyone.
There is demonstrated benefit in specific populations and a labelled indication, but no blanket safety clearance for all heart disease. Review the exact product, contraindications, heart condition, other medicines and tolerability with the treating clinician.
Semaglutide improved symptoms, physical limitations, exercise function and weight in the 52-week STEP-HFpEF trial of people with obesity and preserved-ejection-fraction heart failure. That result does not settle every heart-failure subtype, mortality endpoint or individual treatment decision.
Blood-pressure changes depend on the population and regimen and may require review of existing treatment. They do not establish an additional guaranteed event-reduction percentage. Do not adjust blood-pressure medicines yourself.
It may be used alongside indicated cardiovascular treatment, but every actual regimen deserves review. Do not assume universal absence of interactions or a quantified synergistic benefit. Continue prescribed heart treatment unless the treating clinician changes it.